Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com


Kamada to Commercialize Three Biosimilar Products in Israel

Shots: Kamada signs an agreement with two undisclosed international pharmacies to commercialize three biosimilar product candidates in Israel. The two pharmaceutical companies will be responsible for the development, manufacturing, and supply of three products Following the approval from EMA and IMOH, the three products are expected to be launched in Israel b/w 2022 and 2024 […]Read More


ViewPoints Interview: Janssen’s Kiran Patel Shares Insights on Amivantamab for

In a recent interview with PharmaShots, Kiran Patel, Vice President Clinical Development, Solid Tumor Franchise at Janssen shared his views on the regulatory submission of Amivantamab for the Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations. Shots: Janssen reported the BLA submission to the US FDA seeking approval […]Read More


Teladoc Health and Dexcom Offers CGM-Powered Insight for T2D

Shots: The companies reported that joint Livongo for diabetes and dexcom members will now receive CGM-powered insights that enables members to easily visualize their health information and understand how lifestyle decisions affect their blood glucose levels In Oct’2020, Teldoc merges with Livongo while in Jan’2020 Dexcom collaborated with Livongo to integrate Dexcom’s G6 CGM system […]Read More


UCB Launches Nile AI as a Digital Health Company to

Shots: UCB invested $29.3M in Nile and as majority shareholder, will be the Board of Directors of Nile with future opportunities to acquire insights and data from Nile’s platform Nile is developing a digital epilepsy care management platform and bringing together data to make the epilepsy journey predictable. The platform consists of patient app and […]Read More


Bayer Reports the US FDA’s Acceptance of NDA and Grants

Shots: Bayer Reports the US FDA’s Acceptance of NDA and Grants Priority Review for Finerenone (BAY 94-8862) to Treat CKD and T2D The US FDA granted PR to the therapy, allowing the agency to take action on NDA within 6mos. of acceptance compared to 10mos. under standard review Finerenone is an investigational, non-steroidal, selective MRA […]Read More


ViewPoints Interview: Janssen’s Andrew Greenspan Shares Insights on the Data

In a recent interview with PharmaShots, Andrew Greenspan, MD, VP Medical Affairs of Janssen Immunology shared his views on Janssen’s commitment to advance research in rheumatic disease. Shots: Janssen presented clinical trial results in 35 abstracts featuring findings across PsA, RA, and SLE at ACR Convergence 2020 Virtual Scientific Program Sixteen abstracts focus on Tremfya […]Read More